FDA authorises Laboratorios Rovi to export vaccines manufactured with mRNA technology to the US


Bankinter: After a long process of inspection of its factories, the Company has obtained this authorisation, which makes it possible to manufacture in Spain and sell in the United States Moderna’s anti-COVID vaccine and a next generation of vaccines that Moderna plans to introduce in the market based on the same technology.

Assessment: Very positive news that improves the outlook for Rovi’s third party manufacturing, which already represents approximately 50% of its sales.

ROVI (Buy; Target Price: 80.00; Close: 75.40, Var. Day +0.06%; Var. year: +25.3%).

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.